Eco R1 Capital, LLC Assembly Biosciences, Inc. Transaction History

Eco R1 Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$15.08 - $27.04 $9.13 Million - $16.4 Million	-605,415 Reduced 19.2%	2,548,382 $41.9 Million
Q2 2020 Aug 14, 2020	BUY	$14.57 - $23.96 $8.2 Million - $13.5 Million	563,117 Added 21.74%	3,153,797 $73.5 Million
Q1 2020 May 15, 2020	BUY	$10.27 - $21.23 $2.08 Million - $4.3 Million	202,412 Added 8.48%	2,590,680 $38.4 Million
Q4 2019 Feb 14, 2020	BUY	$8.36 - $23.81 $19.2 Million - $54.6 Million	2,291,668 Added 2372.33%	2,388,268 $48.9 Million
Q3 2019 Nov 14, 2019	SELL	$9.83 - $14.82 $10.4 Million - $15.7 Million	-1,056,999 Reduced 91.63%	96,600 $950,000
Q1 2019 May 15, 2019	SELL	$17.7 - $24.93 $22.1 Million - $31.2 Million	-1,251,254 Reduced 52.03%	1,153,599 $22.7 Million
Q4 2018 Feb 14, 2019	SELL	$19.05 - $36.45 $10.3 Million - $19.6 Million	-538,311 Reduced 18.29%	2,404,853 $54.4 Million
Q2 2018 Aug 14, 2018	SELL	$39.21 - $50.29 $39 - $50	-1 Reduced -0.0%	2,943,164 $115 Million
Q1 2018 May 15, 2018	BUY	$41.7 - $64.16 $41 - $64	1 Added 0.0%	2,943,165 $145 Million
Q3 2017 Nov 14, 2017	BUY	$23.08 - $34.92 $67.9 Million - $103 Million	2,943,164	2,943,164 $103 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $723M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Eco R1 Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Eco R1 Capital, LLC with notifications on news.